Last reviewed · How we verify

Placebo for FP

Organon and Co · Phase 3 active Small molecule Under review

Placebo for FP is a Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for FP (indication not specified).

A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.

Placebo is a small molecule intervention used in clinical trials, typically administered as 0.9% normal saline. It has been studied in various conditions, including Chronic Obstructive Pulmonary Disease, Asthma, and Perennial Allergic Rhinitis, as a control in comparison to other interventions such as rVIIa-FP and Fluticasone Propionate/Formoterol Fumarate.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo for FP
SponsorOrganon and Co
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebos are inert substances used as control comparators in clinical trials to measure the true efficacy of an investigational drug by accounting for psychological and physiological responses to treatment expectation. In this Phase 3 trial for FP (indication unknown), the placebo arm serves to establish baseline response rates and distinguish genuine drug effects from placebo response.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo for FP

What is Placebo for FP?

Placebo for FP is a Small molecule drug developed by Organon and Co, indicated for FP (indication not specified).

How does Placebo for FP work?

A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.

What is Placebo for FP used for?

Placebo for FP is indicated for FP (indication not specified).

Who makes Placebo for FP?

Placebo for FP is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What development phase is Placebo for FP in?

Placebo for FP is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing